Immuron granted US Travelan patent

Immuron (ASX:IMC) has been granted a new US patent covering products including Travelan, its preventative treatment for travellers’ diarrhoea.

The US Patents and Trademarks Office has issued a Notice of Allowance covering one of the company’s patent claims.

Immuron’s patent claims are focused on methods of treating enteric diseases with the company’s hyperimmune colostrum platform technology.

The company is also using the platform to develop treatments for other enteric diseases, including C. difficile and nonalcoholic steatohepatitis (NASH), and the newly granted patent also encompasses these other projects.

“It is reassuring to have this patent in place ... as we continue to progress with our substantive discussions in the United States for the commercialisation of Travelan and related products in the world’s largest market for pharmaceuticals,” Immuron CEO Amos Meltzer said.

“We look forward to achieving further patents around our core technologies in the USA and other key jurisdictions.”

Immuron (ASX:IMC) shares were trading 40% higher at $0.007 as of around 2 pm on Wednesday.